Related references
Note: Only part of the references are listed.The Epidemiology, Diagnosis, and Management of Aristolochic Acid Nephropathy A Narrative Review
M. Refik Goekmen et al.
ANNALS OF INTERNAL MEDICINE (2013)
Enzymes Metabolizing Aristolochic Acid and their Contribution to the Development of Aristolochic Acid Nephropathy and Urothelial Cancer
Marie Stiborova et al.
CURRENT DRUG METABOLISM (2013)
Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool
Song Ling Poon et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing
Margaret L. Hoang et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Biomonitoring of Aristolactam-DNA Adducts in Human Tissues Using Ultra-Performance Liquid Chromatography/Ion-Trap Mass Spectrometry
Byeong Hwa Yun et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2012)
Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid
Bojan Jelakovic et al.
KIDNEY INTERNATIONAL (2012)
Aristolochic acid-associated urothelial cancer in Taiwan
Chung-Hsin Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Bioactivation versus Detoxication of the Urothelial Carcinogen Aristolochic Acid I by Human Cytochrome P450 1A1 and 1A2
Marie Stiborova et al.
TOXICOLOGICAL SCIENCES (2012)
NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I
Katerina Levova et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2012)
Endoplasmic reticulum stress mediates aristolochic acid I-induced apoptosis in human renal proximal tubular epithelial cells
Shaohua Zhu et al.
TOXICOLOGY IN VITRO (2012)
Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats
Alice Zacharova et al.
XENOBIOTICA (2012)
New Anticoagulants in Ischemic Heart Disease
Lawrence Rajan et al.
CURRENT CARDIOLOGY REPORTS (2012)
Conformational changes of the NADPH-dependent cytochrome P450 reductase in the course of electron transfer to cytochromes P450
Tomas Laursen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2011)
Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat
Rostislav Vecera et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2011)
Functional study of the vitamin K cycle in mammalian cells
Jian-Ke Tie et al.
BLOOD (2011)
Role of P450 1A1 and P450 1A2 in Bioactivation versus Detoxication of the Renal Carcinogen Aristolochic Acid I: Studies in Cyp1a1(-/-), Cyp1a2(-/-), and Cyp1a1/1a2(-/-) Mice
Volker M. Arlt et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2011)
The Human Carcinogen Aristolochic Acid I Is Activated to Form DNA Adducts by Human NAD(P)H:quinone Oxidoreductase Without the Contribution of Acetyltransferases or Sulfotransferases
Marie Stiborova et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2011)
Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice
Volker M. Arlt et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
TP53 Mutational signature for aristolochic acid: an environmental carcinogen
Masaaki Moriya et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model
Katerina Levova et al.
TOXICOLOGICAL SCIENCES (2011)
Inhibition of Renal NQO1 Activity by Dicoumarol Suppresses Nitroreduction of Aristolochic Acid I and Attenuates its Nephrotoxicity
Min Chen et al.
TOXICOLOGICAL SCIENCES (2011)
Aristolochic acid I induced oxidative DNA damage associated with glutathione depletion and ERK1/2 activation in human cells
Feng-Yih Yu et al.
TOXICOLOGY IN VITRO (2011)
Coupled Motions Direct Electrons along Human Microsomal P450 Chains
Christopher R. Pudney et al.
PLOS BIOLOGY (2011)
NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector
Albena T. Dinkova-Kostova et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2010)
Cytochrome P450 1A2 Detoxicates Aristolochic Acid in the Mouse
Thomas A. Rosenquist et al.
DRUG METABOLISM AND DISPOSITION (2010)
Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents
Shinya Shibutani et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Aristolochic acid nephropathy: A worldwide problem
Frederic D. Debelle et al.
KIDNEY INTERNATIONAL (2008)
Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy
Marie Stiborova et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2008)
Aristolochic acid mutagenesis:: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer
Volker M. Arlt et al.
CARCINOGENESIS (2007)
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
Arthur P. Grollman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Rat cytochrome P4502C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol
Hiroshi Yamazaki et al.
DRUG METABOLISM AND DISPOSITION (2006)
The environmental pollutant and carcinogen 3-nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are potent inducers of rat hepatic cytochromes P450 1A1 and-1A2 and NAD(P) H:quinone oxidoreductase
Marie Stiborova et al.
DRUG METABOLISM AND DISPOSITION (2006)
Human hepatic and renal microsomes, Cytochromes P450 1A1/2, NADPH:Cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer
M Stiborová et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy
GM Lord et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
Quinone reductases multitasking in the metabolic world
D Ross
DRUG METABOLISM REVIEWS (2004)
Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid:: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase
M Stiborová et al.
CARCINOGENESIS (2003)
Aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer?
VM Arlt et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Aristolochic acid as a probable human cancer hazard in herbal remedies: a review
VM Arlt et al.
MUTAGENESIS (2002)
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat
K Kobayashi et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Regulation of genes encoding NAD(P)H:quinone oxidoreductases
AK Jaiswal
FREE RADICAL BIOLOGY AND MEDICINE (2000)
Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi).
JL Nortier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
